Lung Cancer Study Demonstrates Extremely High Sensitivity of Biocept's Blood-Based Liquid Biopsy Platform in Detecting EGFR Mutation in Plasma with 93% Concordance with Tissue Biopsy

Biocept, Inc.

today announced that findings demonstrating the ability to reliably detect actionable genetic alterations used in the diagnosis, monitoring and treatment of patients with lung cancer using its blood based biopsy, instead of surgical biopsy, will be presented Friday, November 6th, at the Association for Molecular Pathology Annual (AMP) Meeting in Austin, Texas. "The results of this study further demonstrate the ability of Biocept's liquid biopsy platforms to detect the presence of key cancer-associated biomarkers, which can be used in aiding medical decision-making," said Senior